Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience  by Gaballa, Sameh et al.
Table
Patients Characteristics and Outcomes by Diagnosis
Disease type (N) Median
(range) age
Median
(range)
HCT-CI
Remission status Median (range) prior
regimens / N prior auto
Regimen intensity PFS
Follicular (n[ 13) 52 yrs (29-63) 1 (0-4) 5 CR, 5 PR, 3 SD 4 (2-8) / 3/13 (23%) 3 MA 10 NMA 3-yr: 62%
Diffuse large cell (n[ 13) 53 yrs (35-64) 2 (0-6) 8 CR, 4 PR, 1 SD 4 (1-7) / 3/13 (23%) 4 MA 9 NMA 3-yr: 23%
Mantle cell (n[ 5) 57 yrs (37-71) 2 (1-6) 5 CR 3 (2-4) / 4/5 (80%) 5 NMA 2 disease-free
(29-70 months)
Hodgkins (n[ 15) 35 yrs (20-50) 3 (0-5) 10 CR, 3 PR, 1 SD, 1 PD 4 (2-13) / 12/15 (80%) 8 MA 7 NMA 3-yr: 47%
T-cell rich B-cell NHL (n[ 1) 38 yrs 2 PR 7 / No auto 1 MA Died at 1.5 months
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Introduction: Deletion of TP53 genemapped to 17p13, which
can be identiﬁed by conventional cytogenetics or ﬂuorescent
in situ hybridization (FISH), is associated with poor outcome
in multiple myeloma (MM), even after the introduction of
novel agents and the use of high-dose chemotherapy and
autologous (auto) or allogeneic (allo) hematopoietic stem cell
transplantation (HCT). Here we report the outcomes ofTable
TP53 Grp CG
Median age, years (range) 58 (34-69) 58 (31-79)
Sex (M/F) 24/15 62/55
Disease status at time of HCT, %
Relapse 64 42
Other 36 58
HCT type, %
Auto 87 97
Allo 13 3
Diagnosis to HCT >12 months, % 46 42
Maintenance therapy, % 59 62
Figure. Progression free survival.patients (pts) with TP53 deletion (del) on FISH studies who
underwent an auto- or allo-HCT at our institution.
Methods: We identiﬁed 39 pts with MM who had TP53 del
on FISH studies prior to HCT at our institution between 2008
and 2014, and compared their outcomes to a matched con-
trol group (CG) (n¼117) without TP53 del who were treated
during the same time period. Matchingwas based on age and
response to the last therapy prior to HCT.
Results: Patient characteristics are summarized in the
attached Table. The ISS stage at diagnosis was available for 27
pts in the TP53 group (TP53 Grp), 52% of whom had stage III
disease. Most pts in the TP53 Grp had received a proteasome
inhibitor (PI) (95%) or an immune modulatory agent (IMiD)
(72%) prior to HCT. The response to last therapy was either
stable or progressive disease in 36% of patients in both
groups. The median follow-up intervals were 16 and 26
months (m) for the TP53 Grp and CG, respectively. The
median overall survival (OS) in the TP53 Grp was 21 m vs 57
m in the CG; 2-year OS in the TP53 Grp was 46% vs 86% in
the CG (both, P<0.001). Median progression-free survival
(PFS) in the TP53 Grp was 8.5 m vs 28 m in the CG; 2-year
PFS in the TP53 Grp was 18% vs 56% in the CG (both, P<
0.001) (Figure 1). Three of the ﬁve pts in the TP53 Grp who
received an allo-HCT relapsed post-HCT, and none died of
non-relapse causes. In the TP53 Grp, univariate analysis
identiﬁed a trend toward a higher risk of disease
progression in pts who underwent HCT with relapsed
disease (HR¼2.4, 95% CI 0.99-5.8, P¼0.053). Otherwise, age,
response prior to HCT, time from diagnosis to HCT, ISS stage,
allo vs auto HCT, conditioning regimen, cytogenetics, and
prior exposure to PI or IMiD were all non-signiﬁcant factors.
On multivariate analysis for the entire cohort, p53del
(HR¼3.2, 95% CI 1.9-5.3, P<0.001) and relapsed disease at
HCT (HR 2.2, 95% CI 1.3-3.6, P¼0.002) were independent
factors associated with a higher risk of early progression.
Conclusions: In the era of PI, IMiD, and HCT, TP53 del re-
mains a poor prognostic factor in MM. Relapsed disease at
the time of HCT was associated with a higher risk of pro-
gression. Novel approaches and perhaps early allogeneic HCT
require evaluation in this high-risk population.
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